Recent Updates
Recently added Catalysts

Duragesic /h + Scotch Duct Tape

Phase 1

Healthy | Small molecule | Other |Viatris Inc.|Last Updated: Apr 23, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment12
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00650117Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal SystemPHASE1 COMPLETED 12Oct 1, 2006Oct 1, 2006Apr 23, 20241 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Drug Delivery
within 30 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeOTHER
Treatment Arms
ArmTypeDescription
1EXPERIMENTALMylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
2EXPERIMENTALMylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
3EXPERIMENTALMylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
4EXPERIMENTALDuragesic 25 mcg/h + Scotch Duct Tape (3M)
5EXPERIMENTALDuragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
6EXPERIMENTALDuragesic 25 mcg/h + Microfoam Tape (3M)
Interventions
NameTypeDescription
Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)DRUGsingle application
Duragesic 25 mcg/h + Scotch Duct Tape (3M)DRUGsingle application
Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)DRUGsingle application
Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)DRUGsingle application
Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)DRUGsingle application
Duragesic 25 mcg/h + Microfoam Tape (3M)DRUGsingle application
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 21 days prior to the start of the study and on the ev...

Countries:United States
Unlock Eligibility Criteria